AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $210.67, giving the company a market capitalization of 372.49B. It carries a P/E multiple of 87.41 and pays a dividend yield of 3.2%.
As of 2026-04-08, AbbVie(ABBV) stock has fluctuated between $204.56 and $211.64. The current price stands at $210.67, placing the stock +3.0% above today's low and -0.5% off the high.
The AbbVie(ABBV)'s current trading volume is 2.07M, compared to an average daily volume of 6.36M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
AbbVie (ABBV) is suing the Trump administration to get a clearer definition of who counts as an eligible patient in the government’s discount drug program, Maya...
AbbVie is launching Humira on the TrumpRx platform at an 86% discount as part of a new White House agreement to improve drug accessibility and reduce prices. T...
Key Points AbbVie has successfully navigated through a major patent cliff, enabling it to sustain a dividend growth streak for more than a decade. Thanks to t...
Analyst ratings
67%
of 33 ratingsMore ABBV News
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in t...
AbbVie (ABBV) and Roche’s (RHHBY) Genentech unit have become the latest drugmakers to offer their medicines on TrumpRx, a government-run direct-to-consumer plat...
Key Points AbbVie's growth rate has been impressive given the headwinds it has faced. This year, it's forecasting a significant increase in its earnings. 10...
Advertisement What AbbVie’s Recent Share Performance Signals for Investors AbbVie (ABBV) has recently seen a one-month return of about a 10% decline and a pas...
AbbVie (ABBV) and Roche’s (RHHBY) Genentech will be the two latest drug makers to officially begin selling popular commercial medications on the White House’s T...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
In late March 2026, AbbVie detailed extensive new clinical and real-world dermatology data for Skyrizi and Rinvoq at the American Academy of Dermatology meeting...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.